This application is for the Gynecologic Oncology Group (GOG) CCOP Research Base. The GOG is a nonprofit organization promoting excellence in clinical, translational and basic scientific research in the field of gynecologic malignancies. As the premier world-wide clinical trial group in the prevention and treatment of gynecologic cancers, the GOG has developed an active and productive cancer and prevention control program (CPC). The CPC committee was initiated by the GOG in 1995 and has grown to 46 members with an Executive committee developed in 2005 to better guide the development, activation and completion of phase lib and III clinical trials and observational and clinical translational studies. The CPC Executive Committee membership includes the CPC Committee Co-Chairs, ex-officio NCI-Division of Cancer Prevention representatives (Drs. Minasian and Kelaghan), prevention members (Drs. Byron and Garcia), CCOP members (Drs, Rodriguez and Method), members of the Committees on Experimental Medicine and Healthcare Outcome Research and representatives of the GOG Statistical and Data Center and Administrative Office. Meeting by conference call six times yearly, the CPC Executive Committee oversees the work of the CPC disease-site and discipline subcommittees. The GOG affiliate network is made up of primarily community based institutions working under the supervision of a full member institution. In addition, the GOG serves as a research base for 31 CCOPs and 155 CCOP components that provide national clinical trials in many areas of very limited access. The CCOP leaders have direct input to the research directions of Method leads GOG-0224. The CCOPs provide access to patients, and patients in turn are provided access to high quality clinical trial. In addition to providing a strong environment of cancer prevention and treatment research to the CCOP community, the GOG provides, at each of its meetings, cutting edge, in depth workshops and seminars concerning the scientific underpinning for high quality gynecologic and pre cancer management.
Access to oncology clinical trials is a major concern for patients throughout the United States;and adequate accrual to answer important and relevant questions is critical to an ever improving standard of care for patients. Through its network of CCOP institutions, the GOG is able to provide cancer prevention and control trials leading to education and prevention programs designed to foster earlier detection of gynecologic malignancies, suitable early treatment, and eventual elimination of these cancers as a public health risk.
|Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256|
|Sherman, Mark E; Piedmonte, Marion; Mai, Phuong L et al. (2014) Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32:3275-83|
|Alvarez, Ronald D; Sill, Michael W; Davidson, Susan A et al. (2014) A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 133:433-8|
|(2013) Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9:e1003212|
|Bartels, Peter H; Garcia, Francisco A R; Trimble, Cornelia L et al. (2012) Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Gynecol Oncol 125:129-35|
|Farley, John H; Tian, Chunqiao; Rose, G Scott et al. (2010) Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer 116:355-61|
|Markman, Maurie; Brady, Mark; Hutson, Alan et al. (2009) Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Cancer 19:223-9|
|Mutter, George L; Kauderer, James; Baak, Jan P A et al. (2008) Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol 39:866-74|
|Armstrong, Deborah K; Bookman, Michael A; McGuire, William et al. (2007) A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 105:667-71|
|Hess, L M; Barakat, R; Tian, C et al. (2007) Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 107:260-5|